ANDA 208580, held by Pharmobedient. Pantoprazole Sodium.
As of Nov 16, 2026, ANDA 208580 (Pantoprazole Sodium), held by Pharmobedient, was first approved by FDA on May 4, 2018, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 4, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Pantoprazole SodiumEQ 40MG BASE/VIAL · injectable;intravenous | Pantoprazole Sodium | Discontinued |
| Jul 9, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jul 9, 2025 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jul 9, 2025 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jul 9, 2025 | Supplement 7Labeling · Standard review | Approved | None posted |
| Apr 8, 2021 | Supplement 1Labeling · Standard review | Approved | None posted |
| Apr 8, 2021 | Supplement 2Labeling · Standard review | Approved | None posted |
| Apr 8, 2021 | Supplement 3Labeling · Standard review | Approved | None posted |
| May 4, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters